NeuroEPO plus (NeuralCIM®) in mild-to-moderate Alzheimer’s clinical syndrome: the ATHENEA randomized clinical trial

Overview of attention for article published in Alzheimer's Research & Therapy, December 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#46 of 1,531)
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news: 1 news outlet
twitter: 159 X users

reddit: 1 Redditor

Citations

dimensions_citation: 1 Dimensions

Readers on

mendeley: 10 Mendeley

Summary News X Reddit Dimensions citations

So far, Altmetric has seen 1 news story.

NeuroEPO plus (NeuralCIM®) in mild-to-moderate Alzheimer's clinical syndrome: the ATHENEA randomized clinical trial.

Alzforum, 15 Dec 2023

Sosa S, Bringas G, Urrutia N, Peñalver AI, López D, González E, Fernández A, Hernández ZM, Viña A, Peña Y, Batista JF…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.